Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Kyprolis
Carfilzomib is a proteasome inhibitor used to treat multiple myeloma. It works by blocking the action of the proteasome, a cellular complex responsible for breaking down proteins. This disruption leads to the accumulation of abnormal proteins within myeloma cells, ultimately triggering cell death. Carfilzomib is typically administered intravenously and is often used in combination with other anti-cancer agents.
For the treatment of relapsed or refractory multiple myeloma.
Carfilzomib carries a black box warning for cardiac adverse events, including heart failure, cardiac ischemia, hypertension, and arrhythmias. Patients should be monitored for these effects, and dosage adjustments or discontinuation may be necessary.
Outcome:
Increased risk of hyperglycemia
Mechanism:
Both drugs can affect glucose metabolism.
Outcome:
Increased risk of myopathy
Mechanism:
Both drugs can cause muscle damage.
Outcome:
Reduced carfilzomib absorption
Mechanism:
Antacids can alter stomach pH.
Most likely new formulation: Oral Carfilzomib (2026, 60% confidence)
Based on increasing usage in combination therapies and positive clinical trial data, there is a 70% likelihood of expanded indications for Carfilzomib in the next 5 years.
Proteasome Inhibitor, Antineoplastic Agent
Epoxyketone